microRNA-330 (miR-330)

microRNA-330 is a small, non-coding RNA molecule (microRNA) that functions as a post-transcriptional regulator of gene expression, primarily by binding to the 3′ untranslated region (UTR) of target mRNAs, leading to their degradation or inhibition of translation[3]. Widely conserved among eukaryotes, miR-330 regulates hundreds of genes and plays prominent roles in cell proliferation, cell cycle progression, apoptosis inhibition, migration, and invasion. It is upregulated in several cancers, such as non-small cell lung cancer, glioblastoma, and esophageal squamous cell carcinoma, where it acts as an oncogenic factor by targeting tumor suppressors like GRIA3, SH3GL2, and PDCD4[1][2][4]. Elevated miR-330-3p expression is correlated with poor prognosis and increased metastatic potential in cancer patients, and its detection in serum or tumor tissue has been proposed as a prognostic or predictive biomarker. Therapeutic targeting of miR-330, using antisense oligonucleotides (antagomirs), is under experimental investigation, but clinical translation is limited by delivery and specificity challenges[1][2][4].

Other names

MIR330hsa-mir-330mir-330MIRN330miR-330-3p

Post-transcriptional regulation of mRNA; suppresses translation or promotes degradation of specific mRNAs (e.g., GRIA3, SH3GL2, PDCD4); drugs designed to inhibit its function are typically antisense oligonucleotides (antagomirs), which bind and neutralize the microRNA[1][2][4].